Pembrolizumab monotherapy for advanced chordoma - Authors' reply

Lancet Oncol. 2023 Oct;24(10):e400. doi: 10.1016/S1470-2045(23)00454-0.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antineoplastic Agents, Immunological* / adverse effects
  • Chordoma* / drug therapy
  • Humans

Substances

  • pembrolizumab
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological